Soricimed Biopharma Inc.: federal grants and contributions: 10 agreements; $6.3M value; 2 departments; 5 programs.
Assay record ASY-CA-1OXQIO70H8 · Cite as: Assay Systems, “Soricimed Biopharma Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/soricimed-biopharma-inc/
Soricidin-Derived Peptides for Targeted Cancer Management
Provide assistance to mitigate impacts of Covid-19
The project includes preclinical studies required to advance SOR-C13, a clinical stage oncology drug, for the prevention and/or treatment of COVID-19 into clinical trials.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.